shutterstock_627170372.jpg

INNOVATIVE NASAL TREATMENTS IN CNS

DISEASE AREAS

We are targeting two different indications with great unmet patient needs

shutterstock_1462840388.jpg

EPILEPTIC SEIZURES

Epilepsy is responsible for high levels of suffering, affecting more than 50 million people worldwide, thus making it an important public health problem. In Europe, at least 5-6 million people have epilepsy, and 15 million people will have one seizure at some time in their lives. Epileptic seizures affect life conditions drastically and their treatment is of high unmet need. Until now, treatments are formulated as buccal solutions or tablets and suppositories, making their administration in a public area very uncomfortable for caregivers.

CONSCIOUS SEDATION

Anxiety can be found in various clinical settings in which the patient is feeling stressed or has anxiety (e.g. prior radiological diagnostic procedures, prior dentistry procedures, prior anesthetic induction, etc.). Due to its heritage in MRI research, Akroswiss is focusing primarily on the claustrophobia problematic encountered at MRI examinations. In Europe about 50 million MRI scans are performed annually and about 10-20% of patients are affected by anxiety.

shutterstock_476546674.jpg
 
Bi-dose.PNG

SCIENCE

We are developing a new intranasal formulation for a minimal invasive drug administration with a unique 360° feature

FIRST IN CLASS "360° FUNCTIONALITY"

RAPID AND WELL-TOLERATED

NON INVASIVE ADMINISTRATION

SINGLE-USE AND HYGENIC

 

STATUS

Akroswiss is pursuing European marketing authorization of its midazolam product portfolio and is currently compiling all documentation required for EMA submission.

 
 

NEWS

OUR TEAM

Marc_Fr%C3%83%C2%B6hlich_11_edited.png

Chief Executive Officer

download_edited.png

WALTER P. HÖLZLE

Head of Business Development

John%20Fr%C3%B6hlich_edited.png

Founder and Chief Science Officer

Jonas%20Steinhauser_edited.png

Research & Development Director

 
 

CONTACT US

Baarerstrasse 2, 6300 Zug

Phone: +41 (0)41 727 67 87

Mail: info@akroswiss.ch